Perivascular niche for salivary gland cancer stem cells and resistance to therapy
唾液腺癌干细胞的血管周围生态位和治疗耐药性
基本信息
- 批准号:8402545
- 负责人:
- 金额:$ 37.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-10 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AP20187AblationAddressAngiogenesis InhibitorsAnimal ModelAreaBehaviorBlood VesselsBrain NeoplasmsCD44 geneCancer PatientCaringCell LineCellsCessation of lifeCisplatinClinicalDataDevelopmentDiseaseEndothelial CellsExperimental ModelsGoalsHumanImplantIn VitroInterleukin-6LeadMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of salivary glandModalityModelingMolecularMolecular TargetMorbidity - disease rateMucoepidermoid CarcinomaMusNational Institute of Dental and Craniofacial ResearchNormal tissue morphologyOperative Surgical ProceduresOutcomePaclitaxelPatientsPharmaceutical PreparationsPhenotypePilot ProjectsPopulationPublic HealthQuality of lifeRadiation therapyReportingResearchRoleSCID MiceSTAT3 geneSalivary Gland NeoplasmsSalivary GlandsSignal TransductionSorting - Cell MovementStem cellsTestingTherapeuticTissue MicroarrayTransplantationUnited States National Institutes of HealthWorkXenograft ModelXenograft procedurealdehyde dehydrogenasesbasebevacizumabcancer stem cellcaspase-9chemotherapydrug testingeffective therapyenhancing factorhuman diseaseimplantationimprovedin vitro Assaymalignant breast neoplasmmouse modelneoplasticneoplastic cellpreventpublic health relevancereceptorresearch studyresponsescaffoldself-renewalsmall hairpin RNAstemstemnesstherapy resistanttumortumor growthtumor microenvironmenttumor xenografttumorigenesistumorigenic
项目摘要
DESCRIPTION (provided by applicant): The Problem: Approximately 3,300 new cases of salivary gland tumors are reported each year in the USA. Surgery is still the primary treatment modality because chemotherapy and radiotherapy are largely ineffective. As a consequence, the morbidity related to the standard-of-care is high and the 5-year survival for patients with advanced salivary gland cancer is low. Notably, the scarcity of animal models has been recently identified by the NIH/NIDCR as a major impediment for the development of effective therapies for salivary gland cancer. Hypothesis: Cancer stem cells are defined by their ability to self-renew and to generate a phenotypically diverse progeny that recapitulates the tumor of origin. The fact that cancer stem cells can drive tumorigenesis and are resistant to therapy suggests that they may influence the outcome of salivary gland cancer patients. However, little is known about the role of cancer stem cells in the pathobiology of these tumors. In preliminary studies, we identified a sub-population of cells that express high levels of ALDH and CD44 (putative cancer stem cell markers) in human salivary gland tumors. ALDH/CD44 sorting distinguished a sub-population of highly tumorigenic cells from a primary human mucoepidermoid carcinoma and from a neoplastic salivary gland cell line (HSG). Preliminary evidence suggest that endothelial cell-secreted factors enhance the survival and self-renewal of salivary gland cancer stem cells (SGCSC) and that blockade of IL-6 prevent endothelial cell-induced activation of STAT3 (a known regulator of stemness). Notably, the expression of IL-6 and its receptors (IL-6R, gp130) is significantly higher in human salivary gland tumors than in controls. Collectively, these data led to the hypothesis that endothelial cell-initiated signaling is critical for the survival of SGCSC and for response to chemotherapy. To address this hypothesis, we propose the following specific aims: Specific Aim #1: To characterize a xenograft model of salivary gland cancer that is generated by human salivary gland cancer stem cells and is vascularized with functional human blood vessels. Specific Aim #2: To define the effect of endothelial cell-derived IL-6 on the survival and self-renewal of salivary gland cancer stem cells. Specific Aim #3: To study the contribution of the crosstalk between endothelial cells and stem cells on the response of salivary gland tumors to chemotherapy. Significance and Impact: More effective therapies are urgently needed to improve the outcomes of patients with malignant salivary gland cancer. Such therapies are likely to come from studies that enhance the understanding of mechanisms underlying the pathobiology of this disease. Here, we will develop a mouse model of human salivary gland cancer with humanized vasculature and use it to study the role of salivary gland cancer stem cells on response to therapy. Our ultimate goal is to discover new, mechanism-based, therapeutic strategies that improve the survival and quality of life of patients with salivary gland cancer.
描述(由申请人提供):问题:美国每年报告约3,300例新的唾液腺肿瘤病例。手术仍然是主要的治疗方式,因为化疗和放疗在很大程度上无效。因此,与标准治疗相关的发病率较高,晚期涎腺癌患者的5年生存率较低。值得注意的是,NIH/NIDCR最近已将动物模型的稀缺性确定为唾液腺癌有效疗法开发的主要障碍。假设:癌症干细胞的定义是它们自我更新的能力和产生重现肿瘤起源的表型多样性后代的能力。癌症干细胞可以驱动肿瘤发生并对治疗具有抗性的事实表明,它们可能会影响唾液腺癌患者的结果。然而,对癌症干细胞在这些肿瘤的病理生物学中的作用知之甚少。在初步研究中,我们确定了一个亚群的细胞,表达高水平的ALDH和CD 44(推定的癌症干细胞标志物)在人类唾液腺肿瘤。ALDH/CD 44分选区分高度致瘤性细胞的亚群从原发性人类粘液表皮样癌和从肿瘤性唾液腺细胞系(HSG)。初步证据表明,内皮细胞分泌的因子增强了唾液腺癌干细胞(SGCSC)的存活和自我更新,并且IL-6的阻断阻止了内皮细胞诱导的STAT 3(一种已知的干性调节因子)的激活。值得注意的是,IL-6及其受体(IL-6 R,gp 130)的表达在人唾液腺肿瘤中显著高于对照。总的来说,这些数据导致了这样的假设,即内皮细胞启动的信号传导对于SGCSC的存活和对化疗的反应至关重要。为了解决这一假设,我们提出了以下具体目标:具体目标#1:表征由人唾液腺癌干细胞产生并用功能性人血管血管化的唾液腺癌异种移植模型。具体目标#2:确定内皮细胞衍生的IL-6对唾液腺癌干细胞存活和自我更新的影响。具体目标#3:探讨内皮细胞和干细胞之间的相互作用对涎腺肿瘤化疗反应的影响。意义和影响:迫切需要更有效的治疗方法来改善恶性涎腺癌患者的预后。这种疗法可能来自于加强对这种疾病病理生物学机制的理解的研究。在这里,我们将建立一个具有人源化血管系统的人涎腺癌小鼠模型,并使用它来研究涎腺癌干细胞对治疗反应的作用。我们的最终目标是发现新的、基于机制的治疗策略,以提高唾液腺癌患者的生存率和生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacques Eduardo Nor其他文献
Jacques Eduardo Nor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacques Eduardo Nor', 18)}}的其他基金
Metronomic Small Molecule Inhibitor of Bcl2 in Head and Neck Cancer Therapy
Bcl2 节律小分子抑制剂在头颈癌治疗中的应用
- 批准号:
8729053 - 财政年份:2013
- 资助金额:
$ 37.32万 - 项目类别:
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic Car
MDM2/Bcl-2 在腺样囊肿临床前模型中的治疗性抑制
- 批准号:
8444096 - 财政年份:2012
- 资助金额:
$ 37.32万 - 项目类别:
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic Car
MDM2/Bcl-2 在腺样囊肿临床前模型中的治疗性抑制
- 批准号:
8915672 - 财政年份:2012
- 资助金额:
$ 37.32万 - 项目类别:
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic Car
MDM2/Bcl-2 在腺样囊肿临床前模型中的治疗性抑制
- 批准号:
8537888 - 财政年份:2012
- 资助金额:
$ 37.32万 - 项目类别:
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic Car
MDM2/Bcl-2 在腺样囊肿临床前模型中的治疗性抑制
- 批准号:
8712454 - 财政年份:2012
- 资助金额:
$ 37.32万 - 项目类别:
Mechanisms of dental pulp stem cell differentiation into functional endothelium
牙髓干细胞分化为功能性内皮细胞的机制
- 批准号:
8485582 - 财政年份:2011
- 资助金额:
$ 37.32万 - 项目类别:
Perivascular niche for salivary gland cancer stem cells and resistance to therapy
唾液腺癌干细胞的血管周围生态位和治疗耐药性
- 批准号:
8603155 - 财政年份:2011
- 资助金额:
$ 37.32万 - 项目类别:
First Symposium on Head and Neck Cancer Stem Cells
第一届头颈癌干细胞研讨会
- 批准号:
8198917 - 财政年份:2011
- 资助金额:
$ 37.32万 - 项目类别:
相似海外基金
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 37.32万 - 项目类别:
Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 37.32万 - 项目类别:
Standard Grant
Collaborative Research: CDS&E: An experimentally validated, interactive, data-enabled scientific computing platform for cardiac tissue ablation characterization and monitoring
合作研究:CDS
- 批准号:
2245152 - 财政年份:2023
- 资助金额:
$ 37.32万 - 项目类别:
Standard Grant